Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PAM | P19021 | 2/20 | 0.43 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 4/20 | 0.41 |
| ▸ | CES1 | P23141 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286141 | 1.00 | FAAH (0.47) | FAAHALDH1A1PAMDGKACES2 | |
| SCHEMBL9998371 | 0.86 | ALDH1A1 (0.42) | FAAHALDH1A1CES2CES1TSHR | |
| SCHEMBL9998373 | 0.86 | ALDH1A1 (0.42) | FAAHALDH1A1CES2CES1TSHR | |
| SCHEMBL11244910 | 0.81 | PAM (0.56) | ALDH1A1PAMDGKATSHRPRKCA | |
| SCHEMBL3347834 | 0.78 | ALDH1A1 (0.52) | FAAHALDH1A1PAMDGKACES2 | |
| SCHEMBL9998251 | 0.77 | ALDH1A1 (0.46) | FAAHALDH1A1TSHRPTPN1 | |
| SCHEMBL9998249 | 0.77 | ALDH1A1 (0.46) | FAAHALDH1A1TSHRPTPN1 | |
| SCHEMBL4883613 | 0.77 | FAAH (0.51) | FAAHALDH1A1PAMDGKACES2 | |
| SCHEMBL11142138 | 0.77 | FAAH (0.51) | FAAHALDH1A1PAMDGKACES2 | |
| SCHEMBL4879802 | 0.77 | FAAH (0.51) | FAAHALDH1A1PAMDGKACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109609-A1 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | Pierre Fabre Medicament (FR) | 2009-10-21 | — | — | EP | claimed |
| WO-2008107545-A1 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | PIERRE FABRE MEDICAMENT (FR) | 2008-09-12 | — | — | WO | claimed |
| US-20120088917-A1 | NEW QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | MIOSKOWSKI CHARLES (FR) | 2012-04-12 | — | — | US | disclosed |
| EP-2109609-A1 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | Pierre Fabre Medicament (FR) | 2009-10-21 | — | — | EP | disclosed |
| EP-2109609-A1 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | Pierre Fabre Medicament (FR) | 2009-10-21 | — | — | EP | disclosed |
| WO-2008107545-A1 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | PIERRE FABRE MEDICAMENT (FR) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107545-A1 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | PIERRE FABRE MEDICAMENT (FR) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088917-A1 | NEW QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | AZI2, NQO2, SIRT5 | FAAH 2800/4885ALDH1A1 633/4885PAM 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.